Intestinal Genes Expression Associated With Necrotizing Enterocolitis - Trial NCT04073342
Access comprehensive clinical trial information for NCT04073342 through Pure Global AI's free database. This phase not specified trial is sponsored by Assiut University and is currently Not yet recruiting. The study focuses on Neonatal Disease. Target enrollment is 1 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Gene expression of inflammatory mediator (Interleukin 8) and recognition receptor of Toll like receptor (TLR4).
Observational
genetic
Sponsor & Location
Assiut University
Timeline & Enrollment
N/A
Jan 01, 2020
Jun 01, 2022
Primary Outcome
Intestinal gene expression,Toll like receptor 4
Summary
In recent days, necrotizing enterocolitis is one of the most common and devastating problem
 in preterm infants. Therefore, it became a high growing research topic in the last decade.
 
 The development of medical care increases the survival of preterm babies and consequently
 increase the number of cases with this serious problem. A systematic review shows the
 incidence of necrotizing enterocolitis is about 2-7% in babies less than 32weeks gestation
 and 5-22% in baby's birth weight less than 1000gram.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT04073342
Non-Device Trial